RAC Strategic Regulatory Planning 2

Question 1

Which regulatory strategy is most appropriate when a company needs to launch a product simultaneously in the US, EU, and Japan?

Accepted Answer

Global regulatory harmonization strategy using ICH guidelines

Answer

Sequential submissions to each region independently

Answer

Prioritizing the largest market first before others

Answer

Delegating each region to separate uncoordinated teams

Question 2

What is the primary purpose of a Regulatory Affairs Strategic Plan (RASP)?

Accepted Answer

To outline regulatory milestones, resources, and risk mitigation for product development

Answer

To document all adverse events during clinical trials

Answer

To serve as the product labeling master document

Answer

To replace the Quality Management System during development

Question 3

A company is developing a combination product (drug-device). Which US regulatory consideration is most critical early in strategic planning?

Accepted Answer

Determining the primary mode of action to identify the lead FDA Center

Answer

Selecting the most favorable market for launch

Answer

Choosing between 510(k) and PMA pathways regardless of the drug component

Answer

Filing only with CDRH since a device is involved

Question 4

Which tool is commonly used in strategic regulatory planning to assess likelihood and impact of regulatory risks?

Accepted Answer

Risk matrix (probability × impact grid)

Answer

GANTT chart

Answer

SWOT analysis of competitors

Answer

Ishikawa (fishbone) diagram for quality defects

Question 5

A regulatory team is evaluating whether to seek Breakthrough Therapy Designation. What is the key eligibility criterion?

Accepted Answer

Preliminary clinical evidence must show substantial improvement over available therapies for a serious condition

Answer

The drug must treat a rare disease affecting fewer than 200,000 patients

Answer

The product must already have FDA Fast Track status

Answer

Phase 3 trials must be completed with positive results

Question 6

In strategic planning for a generic drug, which factor most significantly determines the regulatory pathway in the US?

Accepted Answer

The brand drug's patent expiration date and market exclusivity status

Answer

Whether the active ingredient has been approved in Europe

Answer

The size of the patient population needing the drug

Answer

The manufacturing site's ISO certification status

Question 7

What is the strategic advantage of using a pre-submission meeting (Type B meeting) with FDA during drug development?

Accepted Answer

It allows sponsors to align on study designs, endpoints, and data requirements before costly investments

Answer

It locks FDA into approving the submission without further review

Answer

It substitutes for formal Phase 2 clinical trial requirements

Answer

It guarantees expedited review timelines post-submission